Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus
May 02 2023 - 08:30AM
Business Wire
Targeted single-dose monoclonal antibody is the first and only
treatment for devastating dog disease
Elanco Animal Health Incorporated (NYSE: ELAN) today announced
the U.S. Department of Agriculture (USDA) has provided a
conditional license for the first Canine Parvovirus Monoclonal
Antibody. This is the first and only approved therapeutic solution
proven to treat canine parvovirus — one of the most contagious and
deadly viruses a dog can contract with a 91% mortality rate if not
treated with supportive carei. The treatment is the first
monoclonal antibody for Elanco, an important innovation platform
for the company.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230427005591/en/
First and only monoclonal antibody
treatment that targets canine parvovirus. (Photo: Business
Wire)
With an estimated 330,000 cases of canine parvovirus available
for treatment in the U.S. annuallyii, clinical trials demonstrate
that the Canine Parvovirus Monoclonal Antibody single, intravenous
dose delivers targeted efficacy in treating this deadly disease.
The treatment can be administered to dogs eight weeks of age or
older with canine parvovirus. The Canine Parvovirus Monoclonal
Antibody treatment may provide a less intensive and more effective
solution than supportive care alone by targeting the virus with
single dose efficacy and a strong safety profile in healthy
dogs.
“Elanco is proud to bring to market this first-in-class
treatment that will help save puppies lives, while alleviating the
emotional and financial burden of both pet owners and veterinary
care teams,” said Jeff Simmons, president and CEO, Elanco. “We’re
excited to bring our first monoclonal antibody treatment to market,
reinforcing Elanco’s commitment to pioneer new tools in spaces
where there aren’t existing options. We’re committed to helping the
world’s pets live longer, healthier lives because we believe making
life better for our pets makes life better.”
The Canine Parvovirus Monoclonal Antibody is expected to begin
shipping in the coming weeks, pending individual state approvals.
Elanco will also continue to provide canine parvovirus education
and resources to veterinarians, shelter owners and pet parents.
“Today’s announcement is a game changer for pet owners and
veterinarians,” said Dr. Kristin Zersen, DVM, DACVECC, assistant
professor of small animal emergency and critical care at Colorado
State University Veterinary Teaching Hospital. “Parvovirus is an
unpredictable disease that causes significant strain on pet owners
and is labor intensive and stressful for shelters and veterinary
clinic staff. It’s lifechanging and industry-defining to be able to
offer a proven solution to canine parvovirus that limits the need
for hospitalization, reducing the impact this disease has on
hundreds of thousands of dogs each year.”
The conditional license approval—granted by the USDA to
effectively and safely meet an emergency situation, limited market
or special circumstance—of the first-ever targeted monoclonal
antibody treatment for canine parvovirus bridges Elanco’s expertise
in both therapeutics and vaccines. In the treatment efficacy study,
the Canine Parvovirus Monoclonal Antibody was proven effective in
decreasing mortality associated with parvovirus infection.iii
Treated dogs also had significantly faster times to resolution of
the most-adverse effects of parvovirus including vomitingiv,
meaning that they feel better faster and get home sooner.
Prior to Elanco’s Canine Parvovirus Monoclonal Antibody, the
only treatment for the highly contagious canine parvovirus was
supportive therapy, which can consist of 24/7 care, multi-day
hospitalization and emotional stress for the staff and pet owner
with no guaranteed outcome and potentially high pet owner costs. In
conjunction with its portfolio of innovative solutions, this
announcement establishes Elanco’s presence in the monoclonal
antibody space and reinforces its commitment to helping pets live
longer, healthier lives through its portfolio of innovative
solutions.
For more information, please visit: FightParvo.com.
ABOUT ELANCO
Elanco Animal Health (NYSE: ELAN) is a global leader in animal
health dedicated to innovating and delivering products and services
to prevent and treat disease in farm animals and pets, creating
value for farmers, pet owners, veterinarians, stakeholders, and
society as a whole. With nearly 70 years of animal health heritage,
we are committed to helping our customers improve the health of
animals in their care, while also making a meaningful impact on our
local and global communities. At Elanco, we’re driven by our vision
of Food and Companionship Enriching Life and our approach to
sustainability, Elanco Healthy Purpose™– all to advance the health
of animals, people, the planet and our enterprise. Learn more at
www.elanco.com.
______________________________
i Venn, E.C. et al. Evaluation of an
outpatient protocol in the treatment of canine parvoviral
enteritis. Journal of Veterinary Emergency and Critical Care. 27(1)
2017, 52-65. doi: 10.1111/vec.12561.
ii Elanco Animal Health. Data on File.
VetSuccess Parvovirus Incidence Analysis
iii Elanco Animal Health. Data on
File.
iv Elanco Animal Health. Data on File.
©2023 Elanco or its affiliates. PM-US-23-0232.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230427005591/en/
Investor Contact: Kathryn Grissom +1.317.273.9284
kathryn.grissom@elancoah.com Media Contact: Season Solorio
+1.765.316.0233 season.solorio@elancoah.com
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Oct 2023 to Nov 2023
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Nov 2022 to Nov 2023